Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07619508 · ClinicalTrials.gov registry record
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 100,000
- Enrollment target
NCT07619508: Completed study, sponsored by Brigham and Women's Hospital.
NCT07619508 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 100,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07619508 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 100,000 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
To evaluate the comparative effect of tirzepatide vs injectable semaglutide on the composite of death, myocardial infarction, or stroke in patients at cardiovascular risk with overweight or obesity but without diabetes treated in clinical practice.
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2026-06-01 |
What the finished NCT07619508 record still lists
NCT07619508 is an observational study that tracks outcomes without assigning an intervention. Its 100,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT07619508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07619508 about?
NCT07619508 is a clinical study titled "Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07619508?
This trial is currently completed. The enrollment target is 100,000 participants. The study started on 2026-02-10. Estimated completion is 2026-06-01.
What interventions are being tested in trial NCT07619508?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07619508?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
- NCT04869111 · 100,000 participants · NA
The BrainHealth Project
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI